Biopharma companies can help healthcare providers and specialist physicians stay abreast of scientific and medical information. Sej Brar describes what it takes to reshape and transform the strategic relevance of the medical affairs function. Related Industry Life Sciences & Pharma
Life Sciences & Pharma Special Report The Evolution of Biomarker Use in Clinical Trials for Cancer Treatments November 26, 2019 The Evolution of Biomarker Use in Clinical Trials for Cancer Treatments: Key Findings and Implications documents the industry’s increasing commitment to…
MedTech COVID-19 Strategic Hospital Priorities in APAC – Emerging Themes and Implications for Medtechs April 1, 2020 With the COVID-19 crisis putting pressure on our healthcare systems, some short-term priorities will have obviously changed.
Life Sciences & Pharma COVID-19 European Disease Progression Monitor: Edition 7 May 26, 2020 The COVID-19 Disease Progression Monitor delivers evidence on the effects of the disease on services, systems and therapies across the Life Sciences and…
Life Sciences & Pharma COVID-19 Pandemic Preparedness During COVID-19: Biopharma Lessons and Future Implications April 24, 2020 The biopharma industry has accelerated research and development (R&D) timelines. However, therapeutics/vaccines in development are projected to launch…
MedTech COVID-19 The New Future of US Telehealth: Lasting Impacts of COVID-19 April 23, 2020 COVID-19 has necessitated a broad increase in telehealth’s role across mainstream care delivery use cases, driven by social distancing, need for virtual…
Life Sciences & Pharma COVID-19 COVID-19 Implications for Biopharma June 25, 2020 This report highlights how biopharma executives should adapt to the evolving biopharma landscape in both the nearer and longer term.
